These results are in line with former studies on lung cancer, acute myeloid leukemia (AML), and bladder cancer showing that NFATc1 inhibition sensitized cancer cells to cisplatin, sorafenib- and tacrolimus-induced apoptosis, respectively [74–76]. Here, NFATC1 is linked to urinary bladder carcinoma.